Visionary Holdings (NASDAQ:GV) filed its audited financial statements for the fiscal year ended March 31, 2025, revealing a significant revenue decline as the company transitions away from its legacy education and real estate businesses toward a high-margin health and anti-aging platform.
The Toronto-based company reported total revenue of $5.04 million, a 46.2% decrease year-over-year.
The drop was largely attributed to a contraction in its real estate leasing segment and a shifting regulatory environment for education services in Canada.
However, management highlighted the first meaningful contributions from its "emerging health" segment, which generated $1.06 million (roughly 21% of total revenue).
This new division focuses on medical-grade anti-aging products, stem cell therapies, and premium medical aesthetics, primarily targeting the Asian market.
The company posted a net loss of $15.75 million for the year, pressured by $4.70 million in asset impairment charges and costs related to its corporate restructuring.
Meanwhile, financial stability remains a primary concern; Visionary disclosed a negative working capital of $54.50 million and several loan defaults.
To address these liquidity pressures, the firm is currently engaged in debt restructuring negotiations and pursuing fresh equity financing.
Despite the financial strain, CEO Xiyong Hou noted that the "validation" of its health-tech revenue provides a foundation for a projected 18-to-24-month path toward scaling its new cellular rejuvenation business.